Results 121 to 130 of about 47,580 (341)

Effect of cell retention techniques in Komagataella phaffii lab‐scale continuous processes

open access: yesBiotechnology Progress, EarlyView.
Abstract Perfusion technologies play a growing role in the implementation of continuous processes for biotherapeutics production in mammalian‐based manufacturing. However, their application to alternative production hosts is limited. Cell retention systems are of key importance for the efficiency of perfusion bioreactors.
Marina Y. Linova   +5 more
wiley   +1 more source

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

open access: yesCancer Management and Research, 2023
Darren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L.
Pan D, Richter J
doaj  

Enhancing CHO cell recombinant protein production using a perfusion‐directed host evolution approach

open access: yesBiotechnology Progress, EarlyView.
Abstract Clonally derived cell lines generated from Chinese hamster ovary (CHO) cells encounter numerous stressors when cultured in high‐intensity perfusion bioreactors leading to poor process performance. To circumvent this, the ability of CHO cells to adapt to different culture environments was exploited. Here host cells were selected in the presence
Peter Amaya   +7 more
wiley   +1 more source

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation

open access: yesFrontiers in Immunology
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu   +27 more
doaj   +1 more source

Human immunodeficiency virus neutralizing antibodies and methods of use thereof [APPLICATION] [PDF]

open access: yes, 2014
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of ...
Bjorkman, Pamela J.   +3 more
core  

Global Burden of Hematologic Malignancies From 1990 to 2021 With Projections to 2030: A Systematic Analysis for the Global Burden of Disease Study 2021

open access: yesiNew Medicine, EarlyView.
ABSTRACT This study aimed to comprehensively analyze the epidemiological trends and global burden of hematologic malignancies (HM) from 1990 to 2021 and to project trends up to the year 2030. Using data from the Global Burden of Disease (GBD) Study 2021, we analyzed the age‐standardized rates (ASRs) and the trends of HM from 1990 to 2021. Decomposition
Ziyuan Shen   +5 more
wiley   +1 more source

High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose

open access: yesFluids and Barriers of the CNS
Background Transferrin receptor (TfR)-mediated transcytosis is a well-established method for delivering biologic therapeutics and diagnostics to the brain.
Gillian Bonvicini   +9 more
doaj   +1 more source

Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition

open access: yesJournal of Immunology Research, 2016
Innovative strategies are necessary to maximize the clinical application of HIV neutralizing antibodies. To this end, bispecific constructs of human antibody F240, reactive with well-conserved gp41 epitope and antibody 14A8, reactive with the IgA ...
Xiaocong Yu   +4 more
doaj   +1 more source

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells [PDF]

open access: gold, 2022
Shuyu Huang   +8 more
openalex   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

open access: yesMedicine Bulletin, EarlyView.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Home - About - Disclaimer - Privacy